Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$978M |
| 2 |
Microsoft
MSFT
|
+$812M |
| 3 |
Bank of America
BAC
|
+$602M |
| 4 |
Apple
AAPL
|
+$518M |
| 5 |
NVIDIA
NVDA
|
+$412M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.32B |
| 2 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$1.12B |
| 3 |
State Street Communication Services Select Sector SPDR ETF
XLC
|
+$958M |
| 4 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$940M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$816M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.45% |
| 2 | Financials | 11.83% |
| 3 | Healthcare | 11.27% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 7.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3776
Lexicon Pharmaceuticals
LXRX
$1.03B
| $42.7K | ﹤0.01% |
39,189
+1,520
| +4% | +$2.67K |
|
|
PSTL
3777
Postal Realty Trust
PSTL
$694M
| $42.6K | ﹤0.01% |
3,156
-566
| -15% | -$8.21K |
|
|
GOEV
3778
DELISTED
Canoo Inc. Class A Common Stock
GOEV
| $42.5K | ﹤0.01% |
189
+50
| +36% | +$12.6K |
|
3779
Sierra Bancorp
BSRR
$528M
| $42.3K | ﹤0.01% |
2,230
-682
| -23% | -$13.4K |
|
3780
Kodak
KODK
$822M
| $42.2K | ﹤0.01% |
10,023
-1,898
| -16% | -$9.29K |
|
|
BNT
3781
Brookfield Wealth Solutions
BNT
$11.8B
| $42.1K | ﹤0.01% |
2,007
-473
| -19% | -$10.7K |
|
|
REFI
3782
Chicago Atlantic Real Estate Finance
REFI
$248M
| $42K | ﹤0.01% |
2,855
-411
| -13% | -$6.21K |
|
3783
LanzaTech
LNZA
$61.2M
| $42K | ﹤0.01% |
90
+49
| +120% | +$32.3K |
|
|
NGM
3784
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $41.6K | ﹤0.01% |
38,861
-1,529
| -4% | -$3.16K |
|
3785
Red Violet
RDVT
$979M
| $41.5K | ﹤0.01% |
2,075
-152
| -7% | -$3.15K |
|
|
CNTA
3786
DELISTED
Centessa Pharmaceuticals
CNTA
| $41.4K | ﹤0.01% |
6,400
| – | – |
|
3787
Ovid Therapeutics
OVID
$414M
| $41.4K | ﹤0.01% |
10,780
-1,175
| -10% | -$4.22K |
|
3788
Prelude Therapeutics
PRLD
$366M
| $41.1K | ﹤0.01% |
13,316
+7,264
| +120% | +$27.3K |
|
|
KALV
3789
DELISTED
KalVista Pharmaceuticals
KALV
| $40.6K | ﹤0.01% |
4,215
-691
| -14% | -$7.06K |
|
3790
Global X Autonomous & Electric Vehicles ETF
DRIV
$377M
| $40.5K | ﹤0.01% |
1,725
| – | – |
|
3791
John Marshall Bancorp
JMSB
$327M
| $40.5K | ﹤0.01% |
2,268
-220
| -9% | -$4.13K |
|
3792
iShares Asia 50 ETF
AIA
$4.6B
| $40.2K | ﹤0.01% |
725
| – | – |
|
3793
Flexsteel Industries
FLXS
$302M
| $40.1K | ﹤0.01% |
+1,930
| New | +$39.4K |
|
3794
STRATTEC Security
STRT
$367M
| $40K | ﹤0.01% |
1,748
+217
| +14% | +$4.88K |
|
|
KLRS
3795
Kalaris Therapeutics
KLRS
$83.5M
| $40K | ﹤0.01% |
809
+2
| +0.2% | +$136 |
|
3796
Nathan's Famous
NATH
$402M
| $40K | ﹤0.01% |
566
| – | – |
|
3797
Pangaea Logistics
PANL
$498M
| $40K | ﹤0.01% |
6,799
-524
| -7% | -$3.27K |
|
3798
Nerdy
NRDY
$106M
| $39.7K | ﹤0.01% |
10,735
-1,060
| -9% | -$4.59K |
|
3799
Red River Bancshares
RRBI
$662M
| $39.6K | ﹤0.01% |
862
-99
| -10% | -$4.8K |
|
3800
Verastem
VSTM
$510M
| $39.4K | ﹤0.01% |
4,847
-21,214
| -81% | -$204K |
|
Similar funds
Barclays's Q3 2023 Portfolio in Review
As of Q3 2023, Barclays held 4,832 positions worth $161B, up 1.7% from $158B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Barclays deployed $8.05B of net new capital in Q3 2023, opening 336 new positions and adding to 1,838 existing holdings. Its largest new stake was CRH: 17,203,754 shares worth $942M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Invesco QQQ Trust, an estimated $1.32B trimmed.
- Barclays's largest Q3 2023 buy was CRH: 17,203,754 shares worth $942M.
- Barclays added most to Microsoft in Q3 2023, an estimated $812M increase.
- Barclays's biggest Q3 2023 reduction was Invesco QQQ Trust, cutting an estimated $1.32B.
- Barclays fully exited Aerojet Rocketdyne Holdings in Q3 2023, selling an estimated $154M.
- Barclays's ten largest holdings make up 24% of its $161B portfolio in Q3 2023.
- Barclays opened 336 new positions and closed 249 in Q3 2023.
- Barclays's portfolio value rose 1.7% quarter-over-quarter to $161B.
Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.